Bristol-Myers Squibb

From Powerbase
Revision as of 13:56, 16 December 2007 by Lynn Hill (talk | contribs) (adding execs - more to come (work in progress))
Jump to: navigation, search

Management

  • James M Cornelius has been a member of the Bristol-Myers Board since January 2005. In April 2007 he was elected chief executive officer for the company’s Board of Directors. [1] His biography reports that 'Cornelius was a member of the Board of Directors of Lilly (Eli Lilly), a member of its Executive Committee and chief financial officer from 1983 to 1995. From 1980-1982, he served as president and CEO of IVAC Corporation, previously a Lilly subsidiary. Cornelius continues to serve on the Boards of Given Imaging Ltd and the DIRECTV Group'.
'responsible for all of Bristol-Myers Squibb’s pharmaceutical operations worldwide, as well as Technical Operations and Global Marketing. Andreotti joined Bristol-Myers Squibb in 1998 as vice president and general manager, Italy and European Oncology. In 2000, he was named president, Europe. In November 2002, Andreotti became senior vice president and president, International. He was appointed to his current position in September 2005. Prior to joining Bristol-Myers Squibb, Andreotti held various senior roles at KABI Pharmacia and then at Pharmacia and Upjohn'.[2]
  • Stephen E Bear - Senior Vice President, Human Resources. Bear's biography for BMS describes how...
'Bear worked for the company from 1985 through May 1999 and held a variety of senior leadership positions in marketing strategy and general management. Notably Bear served as president, Worldwide Consumer Medicines, and executive vice president of Strategy for the Consumer Group. His prior assignments included roles based both in the U.S. and internationally'.[3]
  • Andrew R J Bonfield - Executive Vice President and Chief Financial Officer. Bonfield joined Bristol-Myers Squibb in September 2002. He previously served as director of Finance at the BG Group PLC, an international energy company. Prior to that, he was chief financial officer at SmithKline Beecham (now GlaxoSmithKline) with responsiblity for all aspects of the company’s finances.[4]
  • John E Celentano - President, Health Care Group. Celentano was appointed as president in December 2005. He has responsibility for all of the company’s non- pharmaceutical businesses, including Mead Johnson Nutritionals, ConvaTec and Bristol-Myers Squibb Medical Imaging. Celentano joined the company in 1982 as a sales representative. His biography reports how
'he has risen rapidly through the ranks in sales, market research, product management and general management. In 1994, as a result of the divestiture of Squibb Diagnostics, Celentano left Bristol-Myers Squibb for two years. He rejoined the company as senior director, Anti-Infectives. He was subsequently promoted to general manager, Puerto Rico and the Caribbean. In 1999, Celentano was appointed vice president and general manager, Northern Europe, and in 2002 he was promoted to president, Canada, Mexico and the Caribbean. Celentano’s most recent position was president, Canada and Latin America'.[5]
  • Anthony C Hooper - President, U.S. Pharmaceuticals since January 2004. Hooper's biography states that
'Hooper joined Bristol-Myers Squibb in 1996 as general manager, Bristol-Myers Squibb Australia/New Zealand. He was then promoted to managing director, United Kingdom and Ireland, followed by his role of vice president and general manager for Northern Europe. In 2000 Hooper became President, Asia-Pacific, Middle East and Southern Africa, International Medicines. From 2001 to 2002, he was President, Intercontinental, International Medicines. In 2002 to 2004, Hooper was President, Europe, Middle East and Africa, Worldwide Medicines Group. Prior to joining Bristol-Myers Squibb, Hooper was assistant vice president of Marketing for Wyeth Laboratories International. He also worked for Lederle International in New Jersey, Lederle Laboratories in South Africa and South African Cyanamid Pty. Ltd.[6]

Affiliations

In 2007 Bristol-Myers Squibb (BMS) announced collaboration with Isis Pharmaceuticals Inc. in the development of cardiovascular disease treatment[7].

2007 also saw BMS enter in partnership with Pfizer for a worldwide collaboration to develop and commercialize apixaban (an anticoagulant for the prevention and treatment of a broad range of venous and arterial thrombotic conditions). BMS also reports that 'in a separate agreement, the companies will also collaborate on the research, development and commercialization of a Pfizer discovery program which includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes'.[8]

In February 2007, Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for oncology-related targets[9].

'Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus... Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments'.

BMS also entered into partnership with AstraZeneca in 2007 to 'develop and commercialize' compounds for the treatment of type 2 diabetes[10].

In 2007, Bristol-Myers Squibb also announced an alliance with Gilead Sciences, Inc to commercialize ATRIPLA(R) (for the treatment of HIV-1)[11]. BMS report that, if approved, 'ATRIPLA would represent the first and only once-daily single tablet regimen for HIV-1 infection in the European Union'. In order to commercialize ATRIPLA, Bristol-Myers Squibb reached an agreement with Merck and Co. Inc. who previously had the exclusive right to market any product containing efavirenz (a component of ATRIPLA) in all European countries other than the United Kingdom, Germany, France, Italy, Spain and the Republic of Ireland.

In 2006, Bristol-Myers Squibb Company announced that Otsuka Pharmaceutical Co., Ltd. had been granted exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin (a treatment discovered by BMS for the treatment of Type 2 diabetes).[12]


References

  1. ↑ BMS Corporate Governance - Cornelius Accessed 16th December 2007
  2. ↑ BMS Corporate Governance - Andreotti Accessed 16th December 2007
  3. ↑ Corporate Governance - Bear Accessed 16th December 2007
  4. ↑ BMS Corporate Governance - Bonfield Accessed 16th December 2007
  5. ↑ BMS Corporate Governance - Celentano Accessed 16th December 2007
  6. ↑ BMS Corporate Governance - Hooper Accessed 16th December 2007
  7. ↑ BMS Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals Accessed 16th December 2007
  8. ↑ BMS Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds Accessed 16th December 2007
  9. ↑ BMS Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds Accessed 16th December 2007
  10. ↑ BMS Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds Accessed 16th December 2007
  11. ↑ BMS Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe Accessed 16th December 2007
  12. ↑ BMS Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan Accessed 16th December 2007
Retrieved from "https://powerbase.info/index.php?title=Bristol-Myers_Squibb&oldid=41587"